A5057242083- Hepatitis C virus research
- Hepatitis B Virus Studies
- HIV/AIDS drug development and treatment
- Mobile Ad Hoc Networks
- Liver Disease Diagnosis and Treatment
- Wireless Networks and Protocols
- Energy Efficient Wireless Sensor Networks
- Opportunistic and Delay-Tolerant Networks
- HIV Research and Treatment
- IoT Networks and Protocols
- Cooperative Communication and Network Coding
- HIV/AIDS Research and Interventions
- Energy Harvesting in Wireless Networks
- Cytomegalovirus and herpesvirus research
- Multimedia Communication and Technology
- Bluetooth and Wireless Communication Technologies
- IPv6, Mobility, Handover, Networks, Security
- Caching and Content Delivery
- Advanced Wireless Network Optimization
- Wireless Communication Networks Research
- Blood groups and transfusion
- Peer-to-Peer Network Technologies
- Pneumocystis jirovecii pneumonia detection and treatment
- Context-Aware Activity Recognition Systems
- Video Analysis and Summarization
Banner Life Sciences (United States)
2020-2023
Chimie ParisTech
2021-2022
Laboratoire d'Informatique de Grenoble
2010-2021
Institut polytechnique de Grenoble
2011-2021
Université Grenoble Alpes
2010-2021
Centre National de la Recherche Scientifique
2001-2021
Université Paris Sciences et Lettres
2021
Institut de Recherche de Chimie Paris
2021
Gilead Sciences (United States)
2004-2013
Gilead Sciences (Australia)
2013
The performance of the IEEE 802.11b wireless local area networks is analyzed. We have observed that when some mobile hosts use a lower bit rate than others, all considerably degraded. Such situation common case in which host far away from an access point subject to important signal fading and interference. To cope with this problem, changes its modulation type, degrades value. Typically, products degrade 11 Mb/s 5.5, 2, or 1 repeated unsuccessful frame transmissions are detected. In such...
Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and potent inhibitor of human immunodeficiency virus type 1 reverse transcriptase hepatitis B (HBV) polymerase.
We consider wireless LANs such as IEEE 802.11 operating in the unlicensed radio spectrum. While their nominal bit rates have increased considerably, MAC layer remains practically unchanged despite much research effort spent on improving its performance. observe that most proposals for tuning access method focus a single aspect and disregard others. Our objective is to define an optimized throughput fairness, able dynamically adapt physical channel conditions, operate near optimum wide range...
Human immunodeficiency virus (HIV)-1 infection is associated with progressive cell-mediated immune deficiency and abnormal activation. Although highly active antiretroviral therapy regimens can increase circulating CD4 T lymphocyte counts decrease the risk of opportunistic complications, effects these treatments on reconstitution are not well understood. In 44 persons moderately advanced HIV-1 infection, after 12 weeks treatment zidovudine, lamivudine, ritonavir, plasma RNA fell a median 2.3...
Data are limited on the safety and effectiveness of oral antivirals other than lamivudine adefovir dipivoxil for treatment chronic hepatitis B (CHB) in patients with decompensated liver disease. This Phase 2, double-blind study randomized 112 CHB disease to receive either tenofovir disoproxil fumarate (TDF; n = 45), emtricitabine (FTC)/TDF (fixed-dose combination; or entecavir (ETV; 22). The primary endpoint was safety; more specifically, tolerability failure (adverse events resulting...
Abstract Treatment of 171 patients with hepatitis B e antigen (HBeAg)-positive chronic (CHB) adefovir dipivoxil (ADV) 10 mg over 48 weeks resulted in significant histological, virological, serological, and biochemical improvement compared placebo. The long-term efficacy safety ADV a subset these was investigated for up to 5 years. Sixty-five given year 1 elected continue study (LTSES). At enrollment, the 65 LTSES were median 34 years old, 83% male, 74% Asian, 23% Caucasian, baseline serum...
In this paper, we propose IoTChain, a combination of the OSCAR architecture [1] and ACE authorization framework [2] to provide an E2E solution for secure authorized access IoT resources. IoTChain consists two components, blockchain based on object security model, extended with group key scheme. The provides flexible trustless way handle while uses public ledger set up multicast groups clients. To evaluate feasibility our architecture, have implemented top private Ethereum network. We report...
Human immunodeficiency virus (HIV)–infected South African patients (n=468) received blinded lamivudine or emtricitabine, stavudine, and either nevirapine efavirenz (based on screening viral load). Baseline characteristics were analyzed in univariate multivariate regression, to identify risk factors for hepatotoxicity (grade 3 greater increase serum aminotransferase levels). The occurrence of early was 17% the group 0% balanced between emtricitabine arms. Two subjects died hepatic failure....
In nonalcoholic steatohepatitis (NASH), the extent of hepatocyte apoptosis correlates with disease severity. Reducing selective caspase inhibitor GS-9450 has a potential for altering course liver disease. this phase 2, double-blind study, 124 subjects biopsy-proven NASH were randomized to once-daily placebo or 1, 5, 10, 40 mg 4 weeks. Absolute and percent changes from baseline in ALT levels, AST caspase-3-cleaved cytokeratin (CK)-18 fragments at week assessed by an analysis covariance model...
The effects of 1 year zidovudine, lamivudine, and ritonavir treatment on immune re-constitution were evaluated in 34 human immunodeficiency virus (HIV)-infected individuals. After 48 weeks therapy, 20 (59%) subjects had <100 copies HIV RNA/mL. CD4+ T cells increased from a median 192/mm3 at baseline to 362/mm3 week 48. Lymphocyte prolif-erative responses Candida normalized within 12 weeks, but tetanus remained depressed throughout therapy. Alloantigen then declined levels. Recovery...
Emtricitabine is a nucleoside analogue approved for treatment of human immunodeficiency virus 1 with clinical activity against hepatitis B (HBV).To compare the safety and efficacy emtricitabine placebo in patients HBV, we conducted randomized (2:1), double-blind study at 34 sites North America, Asia, Europe that enrolled adults between November 2000 July 2002 who had chronic HBV infection but never been exposed to or nucleotide treatment. Each patient received either 200 mg (n=167) (n=81)...
Emtricitabine is a new, once-daily nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against human immunodeficiency virus (HIV).To assess the efficacy and safety of emtricitabine as compared stavudine when used background regimen didanosine efavirenz.Randomized, double-blind, double-dummy study conducted at 101 research clinics in North America, Latin Europe. The first patient was enrolled on August 21, 2000; no investigator or unblinded until last randomized completed...
Associations have been reported between an MDR1 variant and responses to nonnucleoside reverse-transcriptase inhibitors. We explored associations MDR1, CYP2B6, CYP3A polymorphisms nevirapine hepatotoxicity. Among participants in a randomized study South Africa (FTC-302), 3435C-->T was significantly associated with decreased risk of hepatotoxicity (risk ratio, 0.30; P=.016).
Current therapies available for the treatment of chronic hepatitis B are limited in their ability to result a cure. Clevudine is new pyrimidine analog with potent anti-hepatitis virus (HBV) activity vitro . A multicenter dose-escalation study evaluated clevudine at 10, 50, 100, and 200 mg once daily 28 days. Eligible patients had HBV DNA levels 3 × 10 6 copies/mL or more, not undergone nucleoside treatment, were without human immunodeficiency C coinfection. Thirty-two enrolled (5, 7 10-,...
We consider wireless LANs such as IEEE 802.11 operating in the unlicensed radio spectrum. While their nominal bit rates have increased considerably, MAC layer remains practically unchanged despite much research effort spent on improving its performance. observe that most proposals for tuning access method focus a single aspect and disregard others. Our objective is to define an optimized throughput fairness, able dynamically adapt physical channel conditions, operate near optimum wide range...
This study investigated the efficacy, safety, and pharmacokinetics of adefovir dipivoxil (ADV) in children adolescents with chronic hepatitis B (CHB). A total 173 treatment-naive treatment-experienced e antigen (HBeAg)+ CHB were randomized to ADV or placebo. Randomization was stratified by age (2 <7 years; >7 <12 >12 <18 years) prior treatment. Significantly more ADV-treated subjects aged 12 years achieved primary efficacy endpoint (serum virus [HBV] DNA <1,000 copies/mL...
Abstract Background TZP ‐102, a potent, oral, ghrelin receptor agonist, improved diabetic gastroparesis symptoms in Phase 2a. Methods Patients with type 1 or 2 diabetes, delayed gastric half‐emptying (T 1/2 ), and ≥3 months randomized : to double‐blind placebo, 10‐mg, 20‐mg ‐102 once daily for 12 weeks (Study ‐102‐ CL ‐G003). Study ‐G004 patients 10‐mg ‐102:placebo three‐times‐daily. Primary endpoint was change‐from‐baseline through Weeks 11–12 Daily Diary of Gastroparesis Symptoms...
Abstract Background Gastroparesis causes significant morbidity and treatment options are limited. TZP‐102 a novel, macrocyclic, selective, oral ghrelin receptor agonist, was evaluated in randomized, double‐blind, placebo‐controlled trial patients with diabetic gastroparesis. Methods A total of 92 outpatients were randomized to once‐daily administrations 10‐mg ( n = 22), 20‐mg 21), 40‐mg 23) or placebo 26). The primary endpoint the change from baseline gastric half‐emptying time T ½ )...